Harpoon Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2018 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Harpoon Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2018 to Q2 2023.
  • Harpoon Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2023 was $1.07M, a 57.5% decline year-over-year.
  • Harpoon Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2023 was $5.49M, a 46.9% decline year-over-year.
  • Harpoon Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $8.64M, a 8.73% decline from 2021.
  • Harpoon Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $9.46M, a 94.7% increase from 2020.
  • Harpoon Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2020 was $4.86M, a 135% increase from 2019.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2023 $5.49M $1.07M -$1.44M -57.5% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-09
Q1 2023 $6.93M $1.13M -$1.71M -60.1% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-11
Q4 2022 $8.64M $1.51M -$1.14M -43% Oct 1, 2022 Dec 31, 2022 10-K 2023-03-27
Q3 2022 $9.77M $1.78M -$560K -23.9% Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-14
Q2 2022 $10.3M $2.5M +$165K +7.06% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 $10.2M $2.84M +$707K +33.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 $9.46M $2.65M +$1.32M +98.9% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-27
Q3 2021 $8.15M $2.34M +$835K +55.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $7.31M $2.34M +$1.16M +98.5% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-10
Q1 2021 $6.15M $2.14M +$1.29M +152% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 $4.86M $1.33M +$689K +107% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-27
Q3 2020 $4.17M $1.5M +$912K +154% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 $3.26M $1.18M +$711K +152% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $2.55M $846K +$477K +129% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $2.07M $643K +$432K +205% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-10
Q3 2019 $1.64M $592K +$418K +240% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-04
Q2 2019 $1.22M $467K +$327K +234% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 $894K $369K +$222K +151% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-06
Q4 2018 $672K $211K Oct 1, 2018 Dec 31, 2018 10-K 2021-03-10
Q3 2018 $174K Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-06
Q2 2018 $140K Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-05
Q1 2018 $147K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.